On Wednesday, Memorial Resource Development Corp (NASDAQ:MRD)’s shares inclined 0.11% to $18.21.
Memorial Resource Development Corp. (MRD) declared that it has priced an underwritten public offering of 12,000,000 shares of its common stock at a price to the public of $17.60 per share. The offering was upsized to 12,000,000 shares of common stock from the original offering size of 10,250,000 shares of common stock. MRD has granted the underwriter an option to purchase up to 1,800,000 additional shares of common stock. MRD intends to use the net proceeds from this offering, and any proceeds from the exercise of the underwriter’s option to purchase additional shares, to fund a portion of the purchase price of MRD’s recently declared pending acquisition of producing and non-producing properties in North Louisiana. If MRD does not complete the pending acquisition, it will use the net proceeds from the offering for general corporate purposes, which may comprise repayment of a portion of the outstanding borrowings under MRD’s senior secured revolving credit facility.
Memorial Resource Development Corp., an independent natural gas and oil company, focuses on the acquisition, exploitation, and development of natural gas, natural gas liquids, and oil properties primarily in North Louisiana.
WaferGen Bio-systems, Inc. (NASDAQ:WGBS)’s shares gained 8.29% to $2.22.
WaferGen Bio-systems (WGBS) presented results from its Single-Cell System at the Single Cell Genomics Conference in Utrecht, The Netherlands. The poster presentation comprised of results from early access collaborators at The University of Texas MD Anderson Cancer Center. The landmark results demonstrated the ability of WaferGen’s Single-Cell System to isolate thousands of single cells and process specific cells of interest for downstream analysis using Next Generation Sequencing (NGS).
The results demonstrated that WaferGen’s Single-Cell system can consistently isolate up to 1,800 single cells per chip and also identify and process individual cells using its automated image analysis software. The Single-Cell system was shown to be capable of isolating various cell types, counting mixtures of K562, U-87 MG, Z138 and Hela cells in experiments designed to mimic the heterogeneous cell types present in complex samples. In additional experiments where two cell types were mixed to contain about 1% of one of the cell types, the Single-Cell System was able to unambiguously identify wells that contained each cell type as evidenced by the analysis of NGS data from ~100,000 sequencing reads per cell.
Data presented in early access experiments performed at Dr. Nicholas Navin’s laboratory at MD Anderson Cancer Center showed that over a thousand SKBR3 cells (a triple negative breast cancer cell line), in addition to nuclei isolated from these cells, can be isolated and dispensed. In additional early access experiments highlighted at the conference, the WaferGen Single-Cell System was capable of isolating and selecting over 13,000 single cells in less than 8 hours using the system’s automated dispensing and image analysis software.
WaferGen Bio-systems, Inc. develops, manufactures, and sells systems for gene expression quantification, genotyping, and stem cell research for the life sciences and pharmaceutical drug discovery industries in the United States, Canada, Europe, and the Asia Pacific.
At the end of Wednesday’s trade, ZIOPHARM Oncology Inc. (NASDAQ:ZIOP)‘s shares surged 3.68% to $12.96.
ZIOPHARM Oncology, Inc. (ZIOP), a biopharmaceutical company focused on the development and commercialization of new cancer immuno-therapies, recently declared the publication of a preclinical study in Cancer Research, a journal of the American Association for Cancer Research, demonstrating the preferential targeting of solid tumor cells over healthy cells using engineered chimeric antigen receptor (CAR) T cells. The article, titled “Tuning sensitivity of CAR to EGFR density limits recognition of normal tissue while maintaining potent anti-tumor activity,” is accessible online first at cancerres.aacrjournals.org, and was highlighted in a press release recently by AACR.
Abnormally-expressed antigens on tumors, such as epidermal growth factor receptor (EGFR) on aggressive brain tumors such as glioblastoma, can be overexpressed relative to lower, basal levels on normal tissues. Taking advantage of this observation, researchers at The University of Texas MD Anderson Cancer Center tuned the binding affinity of CARs to activate T cells based on the density of EGFR expression. The approach was based on the clinical toxicity exhibited by the EGFR-specific antibodies cetuximab and nimotuzumab, which recognize overlapping epitopes and exhibit different kinetics of binding to EGFR. The lower affinity of nimotuzumab has been credited with absence of adverse events relative to cetuximab.
Researchers engineered high-affinity cetux-CAR T cells and low-affinity nimo-CAR T cells, which were tested in vitro on cancer cells with high levels of EGFR, and normal cells with low levels of EGFR. It was found that, while the cetux-CAR T cells killed both cancer and normal cells, the nimo-CAR T cells were selectively activated only in response to cancer cells.
ZIOPHARM Oncology, Inc., a biotechnology company, employs gene expression, control, and cell technologies to deliver cell-based therapies for the treatment of cancer. Its synthetic immuno-oncology programs, in partnership with Intrexon Corporation and the MD Anderson Cancer Center, comprise chimeric antigen receptor T cell (CAR-T) and other adoptive cell based approaches that use both non-viral and viral gene transfer methods for broad scalability.
Avid Technology, Inc. (NASDAQ:AVID), ended its Wednesday’s trading session with -2.45% loss, and closed at $8.17.
Avid(R) (AVID) congratulates its customers on their awards and nominations at the prestigious Primetime Creative Arts Emmy(R) Awards, presented by the National Academy of Television Arts & Sciences (NATAS). As part of the 67th Annual Primetime Emmy Awards, the creative arts awards honor the behind-the-scenes crafts essential to television production.
Avid customers embraced Avid EverywhereTM to create Primetime Emmy Award-winning and nominated productions counting Game of Thrones, Better Call Saul, The Big Bang Theory and Sonic Highways, relying on Avid Artist Suite audio and video applications, powered by the Avid MediaCentral(TM) Platform, to bring their creative visions to the TV screen.
Avid Technology, Inc. develops, markets, sells, and supports software and hardware for digital media content production, administration, and distribution in the United States, the other Americas, Europe, the Middle East, Africa, and the Asia-Pacific.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
